ArticleThe Eurasian journal of medicine2026
PD-1/PD-L1 Expression Could Be a Prognostic Factor in Patients with Acute Myeloid Leukemia.
Article in The Eurasian journal of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn this research, PD-1 and PD-L1 expression patterns were examined to determine their prevalence and prognostic relevance among patients with acute myeloid leukemia (AML).
methodsNinety-nine patients diagnosed with AML at the Hematology Department of Çukurova University Medical School between March 2009 and June 2017 were retrospectively analyzed. The expression levels of PD-1 and PD-L1 in bone marrow biopsy samples were determined using immunohistochemical methods. Their correlations with clinical and laboratory characteristics, treatment response, and survival data were analyzed.
resultsPD-1/PD-L1 positivity (≥ 5%) was observed in 9.1% of the cohort (n = 9). At the time of diagnosis, patients showing PD-1/PD-L1 expression exhibited significantly lower hemoglobin levels than those without expression (7.25 g/dL vs 8.80 g/dL; P = .017). Elevated PD-1/PD-L1 expression correlated with poorer overall survival, with a median OS of 11 months (95% CI: 5.9-16.1) compared to 24 months (95% CI: 13.4-34.6) in the non-expressing group (P = .033).
conclusionAlthough PD-1/PD-L1 expression was relatively infrequent among AML patients, positive cases had significantly poorer survival. These findings suggest that PD-1/PD-L1 expression may be associated with poorer clinical outcomes in AML; however, larger studies are needed to clarify its prognostic relevance. Cite this article as: Varkal G, Gürkan E, Bağır EK, Mete B. PD1/PDL1 expression could be a prognostic factor in patients with acute myeloid leukemia. Eurasian J Med. 2026, 58(4), 1217, doi: 10.5152/ eurasianjmed.2026.251 217.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.